drugset / Trial / NCT04653480
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
NaSingle-groupOpen-labelTreatment
Summary
To determine the efficacy and safety of surufatinib, toripalimab and chemotherapy in second-line RAS/BRAF mutant and MSS colorectal cancer
Timeline
- Start
- 2021-02-01
- Primary completion
- 2025-06
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Surufatinib | Small molecule | 250 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 3 mg/kg | Intravenous |